Gelatin-based biomaterials as a delivery strategy for osteosarcoma treatment
Osteosarcoma is the most common primary malignant bone tumor. Although surgery and chemoradiotherapy have made some progress in the treatment of osteosarcoma. However, the high recurrence and metastasis rate of osteosarcoma and bone defects caused by surgery are still the main problems faced by oste...
Saved in:
| Main Authors: | , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Frontiers Media S.A.
2025-01-01
|
| Series: | Frontiers in Pharmacology |
| Subjects: | |
| Online Access: | https://www.frontiersin.org/articles/10.3389/fphar.2025.1537695/full |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
| _version_ | 1832583701618229248 |
|---|---|
| author | Qifan Yang Xingpeng Chen Jing Liu Yeteng He |
| author_facet | Qifan Yang Xingpeng Chen Jing Liu Yeteng He |
| author_sort | Qifan Yang |
| collection | DOAJ |
| description | Osteosarcoma is the most common primary malignant bone tumor. Although surgery and chemoradiotherapy have made some progress in the treatment of osteosarcoma. However, the high recurrence and metastasis rate of osteosarcoma and bone defects caused by surgery are still the main problems faced by osteosarcoma. Gelatin has excellent biocompatibility and biodegradability, and has made phased progress in tumor treatment. In the treatment of osteosarcoma, gelatin-based biomaterials can be used in delivery strategies to enhance the anti-tumor activity of osteosarcoma and can improve the appropriate compressive strength to improve the bone defects faced after surgery. At present, gelatin-based hydrogels, gelatin scaffolds, and gelatin-based nanoparticles have been reported in preclinical studies. In this article, we introduce the application of gelatin-based biomaterials in the treatment of osteosarcoma, and summarize and look forward to them. |
| format | Article |
| id | doaj-art-20e2ea7e112d487baab767bf87a22ece |
| institution | Kabale University |
| issn | 1663-9812 |
| language | English |
| publishDate | 2025-01-01 |
| publisher | Frontiers Media S.A. |
| record_format | Article |
| series | Frontiers in Pharmacology |
| spelling | doaj-art-20e2ea7e112d487baab767bf87a22ece2025-01-28T06:41:21ZengFrontiers Media S.A.Frontiers in Pharmacology1663-98122025-01-011610.3389/fphar.2025.15376951537695Gelatin-based biomaterials as a delivery strategy for osteosarcoma treatmentQifan Yang0Xingpeng Chen1Jing Liu2Yeteng He3Department of Orthopedics, The First Hospital of Jilin University, Changchun, ChinaDepartment of Orthopaedic Surgery, The First Affiliated Hospital of Shandong First Medical University & Shandong Provincial Qianfoshan Hospital, Jinan, ChinaDepartment of Gynecology and Obstetrics, Jinan Maternity and Child Care Hospital Affiliated to Shandong First Medical University, Jinan, ChinaDepartment of Orthopaedic Surgery, The First Affiliated Hospital of Shandong First Medical University & Shandong Provincial Qianfoshan Hospital, Jinan, ChinaOsteosarcoma is the most common primary malignant bone tumor. Although surgery and chemoradiotherapy have made some progress in the treatment of osteosarcoma. However, the high recurrence and metastasis rate of osteosarcoma and bone defects caused by surgery are still the main problems faced by osteosarcoma. Gelatin has excellent biocompatibility and biodegradability, and has made phased progress in tumor treatment. In the treatment of osteosarcoma, gelatin-based biomaterials can be used in delivery strategies to enhance the anti-tumor activity of osteosarcoma and can improve the appropriate compressive strength to improve the bone defects faced after surgery. At present, gelatin-based hydrogels, gelatin scaffolds, and gelatin-based nanoparticles have been reported in preclinical studies. In this article, we introduce the application of gelatin-based biomaterials in the treatment of osteosarcoma, and summarize and look forward to them.https://www.frontiersin.org/articles/10.3389/fphar.2025.1537695/fullosteosarcomagelatinosteoblastsosteoclastsbone defects |
| spellingShingle | Qifan Yang Xingpeng Chen Jing Liu Yeteng He Gelatin-based biomaterials as a delivery strategy for osteosarcoma treatment Frontiers in Pharmacology osteosarcoma gelatin osteoblasts osteoclasts bone defects |
| title | Gelatin-based biomaterials as a delivery strategy for osteosarcoma treatment |
| title_full | Gelatin-based biomaterials as a delivery strategy for osteosarcoma treatment |
| title_fullStr | Gelatin-based biomaterials as a delivery strategy for osteosarcoma treatment |
| title_full_unstemmed | Gelatin-based biomaterials as a delivery strategy for osteosarcoma treatment |
| title_short | Gelatin-based biomaterials as a delivery strategy for osteosarcoma treatment |
| title_sort | gelatin based biomaterials as a delivery strategy for osteosarcoma treatment |
| topic | osteosarcoma gelatin osteoblasts osteoclasts bone defects |
| url | https://www.frontiersin.org/articles/10.3389/fphar.2025.1537695/full |
| work_keys_str_mv | AT qifanyang gelatinbasedbiomaterialsasadeliverystrategyforosteosarcomatreatment AT xingpengchen gelatinbasedbiomaterialsasadeliverystrategyforosteosarcomatreatment AT jingliu gelatinbasedbiomaterialsasadeliverystrategyforosteosarcomatreatment AT yetenghe gelatinbasedbiomaterialsasadeliverystrategyforosteosarcomatreatment |